Author

Jamie D. Matthews

University of CambridgeORCID 0000-0002-2980-8615Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Suzanne Dawn TurneriD· 3 shared Emily R. JamesiD· 2 shared Lukas KenneriD· 2 shared Michaela SchledereriD· 2 shared Ana‐Iris SchieferiD· 1 shared Anna MalzeriD· 1 shared Bengt HallbergiD· 1 shared Carla Vazquez Amos· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Suzanne Dawn TurnerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

Ruoyan Li, Jamie D. Matthews, Emily R. James, Carla Vazquez Amos, Olli Dufva, Shuang Li, Christopher J. Steel, Lorenz Kretschmer, Chenqu Suo, Philip Turton, Ruth F. Jarrett, Ekaterina M. Shelomentseva, Egor Volchkov, Dmitry Abramov, Maria‐Myrsini Tzioni, , Suzanne Dawn Turner

This study uses single-cell transcriptomics to analyze T cell lymphomas, identifies developmental origins, and discovers SYK and TIM3 as potential therapeutic targets.

bioRxiv · Mar 30, 2026 · PreprintCancer Biology

HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy

Maša Zrimšek, Kristina Draganić, Anna Malzer, Verena Doblmayr, Katarina Mišura, Rafael de Freitas e Silva, Jamie D. Matthews, Fabio Iannelli, Sabrina Wohlhaupter, Carlos Uziel Pérez Malla, Heinz Fischer, Helga Schachner, Ana‐Iris Schiefer, Raheleh Sheibani‐Tezerji, Roberto Chiarle, , Gerda Egger

This study shows HDAC1 suppresses ALK-positive lymphoma growth, but systemic HDAC inhibition can still be therapeutic.

Leukemia · Apr 2, 2025Peer-reviewedCancer Biology

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg, Jamie D. Matthews, Marcus Borenäs, Michaela Schlederer, Leila Jahangiri, Lucy Hare, Christopher Steel, Emily R. James, Nina Prokoph, Lukas Kenner, Ruth Helen Palmer, Bengt Hallberg, G. A. Amos Burke, Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

bioRxiv · Sep 5, 2024 · PreprintCancer Biology